XML 49 R32.htm IDEA: XBRL DOCUMENT
v3.23.1

Corporate and Company information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Corporate and Company information |
Schedule of percentage of equity interest in subsidiary | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | % of equity interest | ​
Name |  | Legal seat |  | Country of incorporation |  | 2022 |  | 2021 | ​
Lava Therapeutics N.V. | ​ | Utrecht | ​ | The Netherlands | ​ | 100 | % | 100 | %
Lava Therapeutics Inc. | ​ | Delaware | ​ | United States of America | ​ | 100 | % | 100 | %
​

X
- Definition The disclosure of information about consolidated structured entities. [Refer: Consolidated structured entities [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Section Nature of the risks associated with an entity's interests in consolidated structured entities -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS12_g14-17__IFRS12_g14-17_TI -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | lvtx_CorporateInformationAbstract
Namespace Prefix: | lvtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration